VBS Pharmaceuticals, a majority owned subsidiary of Vascular BioSciences, advances targeted therapies in order to improve outcomes for patients with difficult to treat diseases.
VBS Pharmaceuticals announces publication of “Peptide-Directed Highly Selective Targeting of Pulmonary Arterial Hypertension.”
VBS Pharmaceuticals welcomes your comments and/or questions.
Develops and manufactures the endoarterial biopsy catheter, the world’s first minimally invasive catheter designed to obtain biopsy samples from the inner layers of arteries percutaneously.